On the Mechanism of Action of Prolylcarboxypeptidase

Shariat-Madar, B.; Taherian, M. R.; Shariat‐Madar, Zia

doi:10.5772/30890

Cited by 5 publications

(3 citation statements)

References 96 publications

(76 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…10 In the RAAS, Ang II and Ang III can constrict blood vessels and raise BP. 35 As a negative regulator of the pressor actions of the RAAS, PRCP could counteract the effects of Ang II and Ang III by degrading them to Ang 1-7 and Ang 2-7 , respectively. 14,17 Thus, inhibiting PRCP might cause a hypertensive state as a result of elevated levels of Ang II and Ang III.…”

Section: Discussionmentioning

confidence: 99%

Genetic association study of prolylcarboxypeptidase polymorphisms with susceptibility to essential hypertension in the Yi minority of China: A case–control study based on an isolated population

Yang

Xiao

2020

J Renin Angiotensin Aldosterone Syst

View full text Add to dashboard Cite

Objective: Prolylcarboxypeptidase (PRCP) is a negative regulator of the pressor actions of the renin–angiotensin–aldosterone system. It is also involved in the kallikrein–kinin system. This gene has an important role in blood pressure (BP) regulation. Methods: A case–control study was performed for 615 Yi participants (303 cases and 312 controls) from a remote mountainous area in Yunnan Province of China. For the PRCP gene, 11 tag single-nucleotide polymorphisms were genotyped using the polymerase chain reaction-restriction fragment length polymorphism method. Results: The PRCP gene rs12290550 was associated with the occurrence of essential hypertension (EH) and BP traits. Logistic regression analysis indicated that the rs12290550 T allele was significantly linked to the risk of EH (odds ratio (OR) = 1.85, 95% confidence interval (CI) 1.44–2.39, p = 0.2 × 10−5). Under Bonferroni correction, the H7 TAGCACTAACA haplotype containing the risk allele rs12290550 T increased the risk of EH (OR = 4.53, 95% CI 2.29–8.93, p = 0.2×10−5). Conclusions: The findings of this study demonstrate the strong association of the PRCP gene with EH. rs12290550 may be a useful genetic predictor of EH in the Yi minority.

show abstract

Section: Discussionmentioning

confidence: 99%

Genetic association study of prolylcarboxypeptidase polymorphisms with susceptibility to essential hypertension in the Yi minority of China: A case–control study based on an isolated population

Yang

Xiao

2020

J Renin Angiotensin Aldosterone Syst

View full text Add to dashboard Cite

show abstract

“…Berbagai biomarker telah diteliti untuk mencari petanda instabilitas aterosklerosis, tetapi dari berbagai tolok ukur tersebut belum ada yang dikatakan memenuhi syarat untuk digunakan dalam pemeriksaan klinis rutin. 25 26 Subjek penelitian di kedua kelompok memiliki komposisi sama dalam gambaran profil faktor kebahayaan yang mempengaruhi tingkat PRCP agar tidak terjadi bias hasil di salah satu kelompok pada penelitian ini. Rancangan seperti ini disebut jenis sejajar dengan penyelerasan.…”

Section: Metodeunclassified

PERBEDAAN KADAR PROLYLCARBOXYPEPTIDASE DI PASIEN SINDROM KORONER AKUT DENGAN PASIEN ANGINA STABIL (The Difference of Prolylcarboxypeptidase Level in Acute Coronary Syndrom and Stable Angina Patient)

Smaratungga¹,

Rita²,

Ar³

et al. 2018

Indonesian J. Clin. Pathol. Med. Lab.

View full text Add to dashboard Cite

Coronary arterial disease (CAD) is the main cause of mortality across many countries throughout the world. Formation ofatherosclerosis plaque is the early cause for cardiovascular dysfunction in CAD. Detecting of atherosclerosis plaque instability is veryimportant to predict the risk of acute coronary syndrome (ACS). Various biomarkers have been studied to find the good marker fordetecting atherosclerosis and its instability, but until now there is no biomarker meet the requirements to be used in routine clinicaltests. Prolylcarboxypeptidase (PRCP) is the alternative parameter in the detection of atherosclerosis, assessing the degree of its plaqueand instability in CAD patients. The benefits of PRCP level test in serum, compared to angiography that is currently used in the detectionof atherosclerosis plaque is that this test is non-invasive, provides quantitative level information, able to estimate the instability of theplaque and the fact that it is a laboratorial test that can be performed in hospitals with less advance facilities. The aim of this study isto know the different PRCP level between ACS and stable angina patients by determination. This study was held in the period betweenMarch–May 2014, in Rumah Sakit dr. Hasan Sadikin Bandung. The subjects were selected on the basis of consecutive sampling onpatients that are presented in the Emergency Departement and Cardiovascular Clinic. From 88 patients consisted of 44 patients withACS and 44 patients with stable angina, were tested for PRCP level in the serum using the ELISA sandwich method. This study wascarried out by observational design with cross sectional method. The statistical analysis uses the Saphiro Wilk data normality test,Mann Whitney test and Kruskal Wallis test. There was no characteristic difference between the two groups. This research identifiedsignificant difference of PRCP level between the ACS group and stable angina (P=0.005). Prolylcarboxy peptidase level in the ACS group(156,3×102 pg/mL) is higher compared to the stable angina (143.8×102pg/mL). PRCP level test hopefully can be recommended asone of the laboratorycal parameter in measuring the degree and instability of atherosclerosis plaque, in the absence of angiography orintravascular ultrasonography test facility.

show abstract

“…ACE2 normally cleaves bradykinin, and thus, low ACE2 causes bradykinin accumulation that may accelerate thrombosis. The knockout of bradykinin receptor B2 can prevent thrombosis in a murine model [7]. Also, ACE2 levels are found to be low in pulmonary thromboembolism.…”

mentioning

confidence: 95%

Reply to Rheumatologists’ perspective on coronavirus disease 19: is heparin the dark horse for COVID-19?

Ahmed

Anirvan

2020

Clin Rheumatol

View full text Add to dashboard Cite

On the Mechanism of Action of Prolylcarboxypeptidase

Cited by 5 publications

References 96 publications

Genetic association study of prolylcarboxypeptidase polymorphisms with susceptibility to essential hypertension in the Yi minority of China: A case–control study based on an isolated population

Genetic association study of prolylcarboxypeptidase polymorphisms with susceptibility to essential hypertension in the Yi minority of China: A case–control study based on an isolated population

PERBEDAAN KADAR PROLYLCARBOXYPEPTIDASE DI PASIEN SINDROM KORONER AKUT DENGAN PASIEN ANGINA STABIL (The Difference of Prolylcarboxypeptidase Level in Acute Coronary Syndrom and Stable Angina Patient)

Reply to Rheumatologists’ perspective on coronavirus disease 19: is heparin the dark horse for COVID-19?

Contact Info

Product

Resources

About